Crinetics Pharmaceuticals, Inc. (CRNX)
NEUTRALFondamental
42
Prix
$84.83
Capitalisation boursière
$9.00B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$42M
12 derniers mois (au 30/06/2026)
Résultat net
$-502M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$-384M
Capitaux propres totaux
$992M
Passif total
$134M
Ratio de liquidité général
15.57
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$85.50
Prix actuel
$84.83
Marge de sécurité
+0.8%
Fourchette de juste valeur
$81.22 - $89.78
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-46.9%
Ratio P/B
7.54
P/FCF
-
Marge brute
86.0%
ROIC
-34.9%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
-34.9%
WACC
8.0%
ROIC − WACC
-42.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (8)
- EPS shows upward trend
- Price CAGR 13.86%
- Gross Margin 86.0%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Revenue Growth 5Y 156.0%
- Net Margin Trend -1189.9% vs -26568.5%
Échoué (11)
- ROIC -34.9%
- P/B Ratio 7.54
- Operating Margin -1302.5%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -44.2%
- Analyst Consensus 33% Buy
- Earnings Surprise avg 2.5%
- Share Dilution 16.2%
- Piotroski F-Score 2/9
Indisponible (8)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. R. Scott Struthers Ph.D. | Founder, President, CEO & Director | 63 |
| Dr. Stephen F. Betz Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Tobin C. Schilke | Chief Financial Officer | 50 |
| Mr. Kea Lingo | Chief Information Officer | - |
| Ms. Gayathri Diwakar | Head of Investor Relations | - |
| Ms. Garlan Adams J.D. | Chief Legal Officer & Corporate Secretary | - |
| Natalie Badillo | Head of Corporate Communications | - |
| Ms. Adriana C. Cabre M.B.A. | Chief Human Resources Officer | - |
| Dr. Alan S. Krasner M.D. | Chief Endocrinologist | 62 |
| Mr. Kevin Capps | Head of Intellectual Property | - |
Risque d'audit
3
Risque du conseil
6
Risque de rémunération
9
Risque droits des actionnaires
8
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for CRNX, sourced from Markets Gazette.
- 2/27/2026NEUTRALCrinetics (CRNX) Q4 2025 Earnings Call Transcript
The financial community is keenly awaiting the transcript of Crinetics Pharmaceuticals' Q4 2025 earnings call, scheduled for February 27, 2026. While the specific content remains unavailable, such events are pivotal for investors, providing crucial details on revenue, earnings per share, and future outlook. Analyzing this data is essential for assessing performance and growth strategies, directly influencing trading decisions for CRNX stock. The current lack of immediate information prevents an in-depth analysis, leaving market participants in anticipation of further disclosures that could move the stock.
via Markets Gazette